DK1392307T3 - Tartratsalte af 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaen - Google Patents

Tartratsalte af 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaen

Info

Publication number
DK1392307T3
DK1392307T3 DK02722625T DK02722625T DK1392307T3 DK 1392307 T3 DK1392307 T3 DK 1392307T3 DK 02722625 T DK02722625 T DK 02722625T DK 02722625 T DK02722625 T DK 02722625T DK 1392307 T3 DK1392307 T3 DK 1392307T3
Authority
DK
Denmark
Prior art keywords
triazatetracyclo
pentaene
hexadeca
tartrate salts
tartrate
Prior art date
Application number
DK02722625T
Other languages
Danish (da)
English (en)
Inventor
Peter Robert Rose
Glenn Robert Williams
David Everett Bogle
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23117845&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1392307(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK1392307T3 publication Critical patent/DK1392307T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/10Antiepileptics; Anticonvulsants for petit-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
DK02722625T 2001-05-14 2002-04-26 Tartratsalte af 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaen DK1392307T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29086101P 2001-05-14 2001-05-14

Publications (1)

Publication Number Publication Date
DK1392307T3 true DK1392307T3 (da) 2005-11-07

Family

ID=23117845

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02722625T DK1392307T3 (da) 2001-05-14 2002-04-26 Tartratsalte af 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaen

Country Status (48)

Country Link
US (2) US6890927B2 (es)
EP (1) EP1392307B1 (es)
JP (1) JP3779682B2 (es)
KR (1) KR100551184B1 (es)
CN (1) CN100370987C (es)
AP (1) AP1473A (es)
AR (1) AR033635A1 (es)
AT (1) ATE302607T1 (es)
AU (1) AU2002253482B2 (es)
BG (1) BG66408B1 (es)
BR (1) BR0209605A (es)
CA (1) CA2447405C (es)
CR (1) CR7080A (es)
CZ (1) CZ304763B6 (es)
DE (1) DE60205742T2 (es)
DK (1) DK1392307T3 (es)
DO (1) DOP2002000392A (es)
EA (1) EA005528B1 (es)
EC (2) ECSP034849A (es)
EE (1) EE05441B1 (es)
EG (1) EG24228A (es)
ES (1) ES2246396T3 (es)
GE (1) GEP20053712B (es)
GT (1) GT200200084A (es)
HK (1) HK1062645A1 (es)
HR (1) HRP20030910B1 (es)
HU (1) HU229867B1 (es)
IL (2) IL157933A0 (es)
IS (1) IS2217B (es)
MA (1) MA27020A1 (es)
ME (1) ME00466B (es)
MX (1) MXPA03010364A (es)
MY (1) MY127807A (es)
NO (1) NO326148B1 (es)
NZ (1) NZ528210A (es)
OA (1) OA12599A (es)
PA (1) PA8545101A1 (es)
PE (1) PE20021065A1 (es)
PL (1) PL214876B1 (es)
PT (1) PT1392307E (es)
RS (1) RS50814B (es)
SI (1) SI1392307T1 (es)
SK (1) SK287170B6 (es)
TN (1) TNSN03113A1 (es)
TW (1) TWI262078B (es)
UA (1) UA73422C2 (es)
WO (1) WO2002092089A1 (es)
ZA (1) ZA200307235B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2301210T5 (es) * 1997-12-31 2015-05-07 Pfizer Products Inc. Compuestos azapolicíclicos condensados con un arilo
IL161857A0 (en) * 2001-11-30 2005-11-20 Pfizer Prod Inc Pharmaceutical compositions of 5,7,14-triazatetracycloÄ10.3.1.0(2,11).0(4,9)Ü-hexadeca-2(11)3,5,7,9-pentaene
MXPA05012507A (es) * 2003-05-20 2006-01-30 Pfizer Prod Inc Composiciones farmaceuticas de vareniclina.
EP1694686A1 (en) * 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
EP1763524A1 (en) * 2004-04-23 2007-03-21 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
JP2008505075A (ja) * 2004-06-30 2008-02-21 イーライ リリー アンド カンパニー 1−(インドール−6−カルボニル−d−フェニルグリシニル)−4−(1−メチルピペリジン−4−イル)ピペラジンd−酒石酸塩
US7550598B2 (en) * 2004-08-18 2009-06-23 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7713973B2 (en) * 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
BRPI0515932A (pt) * 2004-10-15 2008-08-12 Pfizer Prod Inc composições e métodos para distribuição intranasal, bucal, sublingual e pulmonar de vareniclina
US20080275051A1 (en) * 2005-02-24 2008-11-06 Busch Frank R Preparation of High Purity Substituted Quinoxalines
US20110086086A1 (en) * 2005-07-26 2011-04-14 Pfizer Inc Transdermal system for varenicline
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2009508880A (ja) * 2006-02-21 2009-03-05 テバ ファーマシューティカル インダストリーズ リミティド アルモダフィニルの新規な結晶形とその調製方法
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
SG175609A1 (en) 2006-10-09 2011-11-28 Takeda Pharmaceutical Kinase inhibitors
AU2007319951A1 (en) * 2006-11-09 2008-05-22 Pfizer Products Inc. Polymorphs of nicotinic intermediates
US20090062257A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched varenicline
US20090105346A1 (en) * 2007-10-02 2009-04-23 Alexandr Jegorov Novel crystalline forms of armodafinil and preparation thereof
US20090215787A1 (en) * 2008-02-22 2009-08-27 Mai De Ltd. Preparations of new polymorphic forms of varenicline tartrate
EP2262780A4 (en) * 2008-03-06 2012-01-25 Reddys Lab Ltd Dr TARTRATE OF VARENICLINE AMORPHOUS
US8440825B2 (en) 2008-03-06 2013-05-14 Medichem S.A. Fumaric acid salt of varenicline
EP2271344A4 (en) 2008-03-31 2011-04-27 Univ South Florida METHODS OF TREATING DISEASE INDUCED ATAXIA AND NON-ATAXIC IMBALANCE
CA2709774C (en) 2008-05-22 2012-10-02 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20090318460A1 (en) * 2008-05-26 2009-12-24 Glenmark Amorphous varenicline tartrate and process for the preparation thereof
US20090318695A1 (en) * 2008-06-19 2009-12-24 Vinod Kumar Kansal Processes for the preparation of varenicline and intermediates thereof
WO2010005643A1 (en) * 2008-07-10 2010-01-14 Teva Pharmaceutical Industries Ltd. Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
WO2010023561A1 (en) * 2008-09-01 2010-03-04 Actavis Group Ptc Ehf Process for preparing varenicline, varenicline intermediates, and pharmaceutically acceptable salts thereof
CA2801842A1 (en) 2009-06-10 2010-12-16 Actavis Group Ptc Ehf Amorphous varenicline tartrate co-precipitates
EP2438054A1 (en) * 2009-06-22 2012-04-11 Teva Pharmaceutical Industries Ltd. Solid states forms of varenicline salts and processes for preparation thereof
CA2791460A1 (en) 2010-03-09 2011-09-15 Actavis Group Ptc Ehf Highly pure varenicline or a pharmaceutically acceptable salt thereof substantially free of methylvarenicline impurity
WO2011140431A1 (en) 2010-05-06 2011-11-10 Teva Pharmaceutical Industries Ltd. Varenicline salts and crystal forms thereof
JP5925381B2 (ja) 2012-04-13 2016-05-25 ▲連雲▼港金康和信▲薬業▼有限公司Lianyungang Jinkang Hexin Pharmaceutical Co., Ltd. 化合物[4−(2−アミノ−10−メチル−4−オキソ−6,7,8,9−テトラヒドロ−4a,7−エピミノピリミド[4,5−b][1,4]ジアゼピン−5(4H)−イル)ベンゾイル]−グルタメート及びその製造
KR101663550B1 (ko) * 2014-06-11 2016-10-07 조선대학교산학협력단 주석산을 유효성분으로 포함하는 고혈압 예방 또는 치료용 약학조성물 및 건강기능식품
KR101724301B1 (ko) 2016-11-22 2017-04-10 주식회사 한서켐 바레니클린 살리실산염의 i형 결정 및 그 제조방법
WO2018154395A2 (en) 2018-06-11 2018-08-30 Alvogen Malta Operations (Row) Ltd Controlled release pharmaceutical composition of varenicline
TW202206078A (zh) 2020-04-28 2022-02-16 美商奧伊斯特普安生物製藥公司 局部投與菸鹼乙醯膽鹼受體促效劑用以抑制冠狀病毒感染
JP2024537595A (ja) 2021-08-20 2024-10-16 威智医薬股▲フン▼有限公司 ニトロソアミン不純物、ニトロソアミン不純物の生成を低減できるバレニクリン医薬組成物とその調製及び応用
KR20230068877A (ko) 2021-11-11 2023-05-18 주식회사 아울바이오 고용량 바레니클린을 포함하는 미립구 및 이의 제조방법 및 이를 포함하는 약학적 조성물
CN113980020B (zh) * 2021-11-22 2023-05-09 浙江车头制药股份有限公司 一种酒石酸伐尼克兰晶型的制备方法
WO2023275413A2 (en) 2021-12-23 2023-01-05 Medichem, S.A. Solid pharmaceutical formulations of varenicline
EP4241775A1 (en) 2022-03-11 2023-09-13 Par Pharmaceutical, Inc. Tablet comprising varenicline and process of preparation thereof
US11602537B2 (en) 2022-03-11 2023-03-14 Par Pharmaceutical, Inc. Varenicline compound and process of manufacture thereof
WO2023244574A1 (en) 2022-06-14 2023-12-21 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use
WO2024095172A1 (en) 2022-11-04 2024-05-10 Pfizer Inc. Prodrugs of varenicline and compounds containing vulnerable amines
KR20240115109A (ko) 2023-01-18 2024-07-25 주식회사 아울바이오 고용량 바레니클린을 포함하는 미립구 및 이의 제조방법 및 이를 포함하는 약학 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471503A (en) 1967-05-05 1969-10-07 Mcneilab Inc 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols
ES2301210T5 (es) * 1997-12-31 2015-05-07 Pfizer Products Inc. Compuestos azapolicíclicos condensados con un arilo
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
YU34501A (sh) * 2000-05-26 2003-10-31 Pfizer Products Inc. Postupak reaktivne kristalizacije radi povećanja veličine čestica

Also Published As

Publication number Publication date
ES2246396T3 (es) 2006-02-16
EG24228A (en) 2008-11-10
CA2447405A1 (en) 2002-11-21
HK1062645A1 (en) 2004-11-19
KR100551184B1 (ko) 2006-02-13
RS50814B (sr) 2010-08-31
BG66408B1 (bg) 2014-01-31
NO326148B1 (no) 2008-10-06
AP2002002523A0 (en) 2002-06-30
CN1509174A (zh) 2004-06-30
EE05441B1 (et) 2011-08-15
DOP2002000392A (es) 2002-11-15
ZA200307235B (en) 2004-09-16
HUP0304088A2 (hu) 2004-04-28
GT200200084A (es) 2003-09-12
IS2217B (is) 2007-03-15
EA200301121A1 (ru) 2004-02-26
HRP20030910B1 (en) 2011-11-30
YU86703A (sh) 2006-05-25
EP1392307B1 (en) 2005-08-24
MY127807A (en) 2006-12-29
ME00466B (me) 2011-10-10
EP1392307A1 (en) 2004-03-03
NO20035036L (no) 2003-11-13
DE60205742T2 (de) 2006-05-11
ECSP034850A (es) 2003-12-24
IL157933A0 (en) 2004-03-28
AP1473A (en) 2005-09-30
EA005528B1 (ru) 2005-04-28
WO2002092089A1 (en) 2002-11-21
US6890927B2 (en) 2005-05-10
BR0209605A (pt) 2004-03-23
CA2447405C (en) 2006-10-17
PT1392307E (pt) 2005-11-30
BG108343A (bg) 2004-12-30
KR20040010638A (ko) 2004-01-31
IL157933A (en) 2013-07-31
HU229867B1 (en) 2014-10-28
PL214876B1 (pl) 2013-09-30
SI1392307T1 (sl) 2005-12-31
NZ528210A (en) 2005-04-29
CN100370987C (zh) 2008-02-27
JP3779682B2 (ja) 2006-05-31
ATE302607T1 (de) 2005-09-15
CZ304763B6 (cs) 2014-10-01
PE20021065A1 (es) 2002-11-21
SK13362003A3 (en) 2004-11-03
US7265119B2 (en) 2007-09-04
US20030166701A1 (en) 2003-09-04
JP2004533446A (ja) 2004-11-04
UA73422C2 (en) 2005-07-15
DE60205742D1 (de) 2005-09-29
TWI262078B (en) 2006-09-21
HUP0304088A3 (en) 2011-11-28
GEP20053712B (en) 2005-12-26
ECSP034849A (es) 2003-12-24
PA8545101A1 (es) 2003-09-05
TNSN03113A1 (fr) 2005-12-23
EE200300556A (et) 2004-04-15
HRP20030910A2 (en) 2004-02-29
MA27020A1 (fr) 2004-12-20
OA12599A (en) 2006-06-08
SK287170B6 (sk) 2010-02-08
NO20035036D0 (no) 2003-11-13
CZ20032916A3 (cs) 2004-09-15
US20050148591A1 (en) 2005-07-07
IS6957A (is) 2003-09-15
MXPA03010364A (es) 2004-03-16
AU2002253482B2 (en) 2007-09-06
CR7080A (es) 2006-08-09
AR033635A1 (es) 2003-12-26
PL366551A1 (en) 2005-02-07

Similar Documents

Publication Publication Date Title
DK1392307T3 (da) Tartratsalte af 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaen
DK1448235T3 (da) Orale, farmaceutiske sammensætninger af 5,8,14-triaza-tetracyclo[10.3.1.0(2,11).0(4.9)]-hexadeca-2(11),3,5,7,9-pentaen med kontrolleret frigivelse
NO20043174L (no) Pyrido[2,1-a]isokinolinderivater som DPP-IV inhibitorer
MA26819A1 (fr) Pteridinones servant d' inhibiteurs de kinases.
EE200300557A (et) 5,8,14-triasatetratsüklo [10,3,1,0 2,11 ,0 4,9]heksadeka-2(11),3,5,7,9-pentaeeni tsitraatsool
HK1052703A1 (en) Salts of bicyclic, n-acylated imidazo-3-amines andimidazo-5-amines.
NO20014050D0 (no) 1-aryl-1,3,5-triazin-4-tion-2,6-dioner, fremstilling derav og anvendelse derav som herbicider
NO20034529L (no) 3,7-diazabicyklo(3,3,1) - formuleringer som anti-arytmi- forbindelser
ES1049590Y (es) Cenicero ambientador perfeccionado.
FR2827597B1 (fr) Sels de 1,9-diarylheptamethine
ITTO20010077V0 (it) Gruppo vasca per trattamenti di decapaggio.
ES1048644Y (es) Colgador de sobremesa perfeccionado.
DK1289996T3 (da) Heteroaryldiazabicycloalkaner som nicotiniske cholinergiske receptorligander
ES1049836Y (es) Barandilla perfeccionada.